ENOV logo

Enovis Corporation Stock Price

NYSE:ENOV Community·US$1.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

ENOV Share Price Performance

US$22.71
-9.07 (-28.54%)
US$42.30
Fair Value
US$22.71
-9.07 (-28.54%)
46.3% undervalued intrinsic discount
US$42.30
Fair Value
Price US$22.71
AnalystConsensusTarget US$42.30
AnalystHighTarget US$58.00
AnalystLowTarget US$33.00

ENOV Community Narratives

·
Fair Value US$42.3 46.3% undervalued intrinsic discount

Next Generation Orthopedic Technology Will Transform Global Care

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
·
Fair Value US$58 60.8% undervalued intrinsic discount

Recon And Enabling Technologies Will Drive Significant Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$33 31.2% undervalued intrinsic discount

Delayed Launches And Integration Risks Will Restrain Orthopedics Despite Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$42.3
46.3% undervalued intrinsic discount
Profit Margin
4.66%
Future PE
26.59x
Price in 2029
US$55.01
US$58
60.8% undervalued intrinsic discount
Profit Margin
14.34%
Future PE
11.52x
Price in 2028
US$76.8

Trending Discussion

Updated Narratives

ENOV logo

ENOV: Q1 Execution And FY26 Free Cash Flow Will Drive Upside

Fair Value: US$42.3 46.3% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ENOV logo

Recon And Enabling Technologies Will Drive Significant Long Term Upside Potential

Fair Value: US$58 60.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ENOV logo

Delayed Launches And Integration Risks Will Restrain Orthopedics Despite Demand

Fair Value: US$33 31.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

0 Risks
3 Rewards

Enovis Corporation Key Details

US$2.3b

Revenue

US$888.5m

Cost of Revenue

US$1.4b

Gross Profit

US$2.5b

Other Expenses

-US$1.1b

Earnings

Last Reported Earnings
Apr 03, 2026
Next Reporting Earnings
n/a
-19.72
61.00%
-49.83%
89.6%
View Full Analysis

About ENOV

Founded
1995
Employees
7802
CEO
Damien McDonald
WebsiteView website
www.enovis.com

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Recent ENOV News & Updates

Narrative Update Jun 24

ENOV: Q1 Execution And FY26 Free Cash Flow Will Drive Upside

Enovis now carries a slightly lower analyst price target of $42.30, down from $43, as analysts factor in modest adjustments to discount rates, revenue growth expectations, profit margins, and future P/E assumptions following recent research updates from several firms. Analyst Commentary Recent research on Enovis points to a mixed but focused view, with analysts fine tuning price targets and ratings as they reassess the company’s execution and valuation assumptions.
Analysis Article Jun 17

Enovis (ENOV) Stock Could Be 49.8% Undervalued After Spinamic Brace Launch

Enovis stock reaction to the new Spinamic scoliosis brace launch Enovis (ENOV) has drawn fresh investor attention after launching the DonJoy Spinamic Hybrid Scoliosis Brace, a hybrid rigid and soft brace for adolescent idiopathic scoliosis that is now available in the United States. See our latest analysis for Enovis. For context, Enovis shares have pulled back over the year, with the year to date share price return down 18.6% and the 1 year total shareholder return down 30.1%, so the recent...

Recent updates

No updates